Closed Loop Medicine appoints Paul Johnson as Non-Executive Director
May 22, 2024 – Biotechnology, Pharmaceutical – Appointment, Closed Loop Medicine, TechBio
- Appointment of digital healthcare leader to Board to support the company as it enters next phase of commercial development
- Co-founder and former CEO of Lemonaid Health, a leading innovator in telemedicine and prescription drug delivery, acquired by 23andMe in 2021
22 May 2024 — London, UK — Closed Loop Medicine, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, today announced the appointment of Paul Johnson as an independent non-executive director. A notable entrepreneur in the industry, Paul brings unique and extensive experience in the development and scaling of digital healthcare and e-commerce platforms to the Board of Directors. He joins at a pivotal stage in the company’s development as it prepares for breakthrough milestones in the progression and commercialisation of its product pipeline.
Paul is an established leader within the digital healthcare industry, having co-founded Lemonaid Health, one of the first national direct-to-consumer telehealth apps in the US, and led the company as CEO through to its acquisition by consumer genetics and research company, 23andMe, for $400m in 2021. Paul then became VP and general manager, and later COO, of the wider 23andMe consumer business, which includes Lemonaid Health, providing its innovative telemedicine platform to advance 23andMe’s vision of individualised primary care. Prior to moving to the US, Paul was head of Online at McKesson UK, where he was responsible for the online P&L and all digital activity for the group’s brands, including Lloyds Pharmacy. In 2010, as UK managing director, he launched the Zooplus business in the UK, Europe’s leading online pet shop. Paul is an advisor to several technology-first companies and leading venture funds, he is a CEO coach and an active angel investor.
Harnessing his specialist experience and expertise in digital platforms and direct-to-consumer medical services, Paul joins Closed Loop Medicine’s Board to support the leadership team in driving forward the commercialisation strategy for its portfolio of integrated precision care solutions. His appointment is the third leadership-level appointment within the past year and follows several recent commercial milestones, including publication of breakthrough clinical trial data validating use of the company’s proprietary technology to identify personalised dose regimens in the treatment of hypertension, leading to improved blood pressure control and exceptionally high medication adherence. The findings will be applied as the company further extends its pipeline of combination products across other therapeutic areas including in obesity to provide a patient-centred dose optimisation tool for robust differentiation in the GLP-1 market.
Paul Johnson, non-executive director of Closed Loop Medicine, commented: “Closed Loop Medicine’s approach to delivering personalised and integrated healthcare aligns with my commitment to building digital product experiences that treat patients as individuals, rather than an average of a population set. Throughout my career, I’ve championed digital solutions to provide accessible healthcare for all. With its proprietary dose optimisation platform, the company is going a step further to improve outcomes at the individual level.” He added: “It is clear I am joining Closed Loop Medicine at a very transformative stage in its development, and I am very much looking forward to supporting the company in bringing forward the promise of precision care, as it realises the potential of its product pipeline.”
Dr Hakim Yadi PhD OBE, CEO & co-founder of Closed Loop Medicine, said: “As we stand on the brink of realising our vast prospects within the industry, Paul’s strategic insights and proven track record will be instrumental to steering the company to continued growth and success. His notable achievements and deep expertise in navigating the evolving telemedicine and digital health landscape, particularly through his work at Lemonaid Health and 23andMe, will undoubtedly play a focal role in bolstering the company’s strategic growth and commercialisation of our disruptive platforms.”
About Closed Loop Medicine
Closed Loop Medicine is a TechBio company developing combination prescription drug plus software products, with the aim of bringing forward the promise of precision care. The company’s proprietary technology platform facilitates personalised and optimised dosing, through integration of medicines and software with patient-led digital experiences and closed loop models of care. This approach to treating the individual, not just the disease, has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Founded at the Babraham Institute in Cambridge, UK, in 2017, and now based in London, UK, Closed Loop Medicine’s investors include Ananda Impact Ventures, BGF, LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels. To learn more about Closed Loop Medicine and its mission to deliver precision care for all, please visit: www.closedloopmedicine.com
